Drug Approval | May 04, 2022
Gland launches Bortezomib in the US market
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
As a global mushroom biotechnology group, Mycelium Biotechnology is engaged in mushroom growing, global distribution and offering biotechnology and nutraceutical solutions through global partners
The announcement follows FDA 510(k) clearance of device
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Avacc 3 has significant advantages over existing whooping cough vaccines
Subscribe To Our Newsletter & Stay Updated
